ReviewMedChemComm2018
Approaches to target tractability assessment - a practical perspective.
Review in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure.Nature communications · 2023Pooled it
- Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation.PloS one · 2021Pooled it
- Integrative proteogenomic analyses identify plasma proteins that impact the risk of ischemic stroke.Communications medicine · 2026Article
- An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression.Translational psychiatry · 2026Article
- PROTAC-based protein degradation: a window of opportunity for melanoma therapy.Journal of biomedical science · 2026Review
- Aptamer-Mediated Covalent Dual Lysosome-Targeting Chimeras Enhance Targeted Degradation of Cell Surface Proteins.JACS Au · 2026Article
- Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions.Molecular psychiatry · 2025Article
- The genetic overlap between major depressive disorder, white blood cell counts and interleukin 6.Journal of affective disorders reports · 2025Article
- PROteolysis TArgeting Chimeras (PROTACs) and beyond: targeted degradation as a new path to fight microbial pathogens.FEMS microbiology reviews · 2025Review
- Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.Genome medicine · 2024Article
- PWAS Hub for exploring gene-based associations of common complex diseases.Genome research · 2024Article
- Review
- Strategies for translating proteomics discoveries into drug discovery for dementia.Neural regeneration research · 2024Review
- Integrative GWAS and co-localisation analysis suggests novel genes associated with age-related multimorbidity.Scientific data · 2023Article
- A publication-wide association study (PWAS), historical language models to prioritise novel therapeutic drug targets.Scientific reports · 2023Article
- Multiplatform-Integrated Identification of Melatonin Targets for a Triad of Psychosocial-Sleep/Circadian-Cardiometabolic Disorders.International journal of molecular sciences · 2023Article
- Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C.RSC medicinal chemistry · 2022Article
- Increased slow dynamics defines ligandability of BTB domains.Nature communications · 2022Article
- Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.Nature communications · 2022Article
- Systematic illumination of druggable genes in cancer genomes.Cell reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment of the suitability of novel targets to intervention by different modalities,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.